Skip to main content
SpringerLink
Log in

Immunotherapy for Melanoma

  • Chapter
  • First Online:
Immunotherapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1342))

Abstract

Melanoma is the leading cause of death from skin cancer and is responsible for over 7000 deaths in the USA each year alone. For many decades, limited treatment options were available for patients with metastatic melanoma; however, over the last decade, a new era in treatment dawned for oncologists and their patients. Targeted therapy with BRAF and MEK inhibitors represents an important cornerstone in the treatment of metastatic melanoma; however, this chapter carefully reviews the past and current therapy options available, with a significant focus on immunotherapy-based approaches. In addition, we provide an overview of the results of recent advances in the adjuvant setting for patients with resected stage III and stage IV melanoma, as well as in patients with melanoma brain metastases. Finally, we provide a brief overview of the current research efforts in the field of immuno-oncology for melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Tas, F., Keskin, S., Karadeniz, A., Dagoglu, N., Sen, F., Kilic, L., & Yildiz, I. (2011). Noncutaneous melanoma have distinct features from each other and cutaneous melanoma. Oncology, 81(5–6), 353–358. https://doi.org/10.1159/000334863

    Article  PubMed  Google Scholar 

  2. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. CA: a Cancer Journal for Clinicians, 71(1), 7–33. https://doi.org/10.3322/caac.21654

    Article  Google Scholar 

  3. McCourt, C., Dolan, O., & Gormley, G. (2014). Malignant melanoma: A pictorial review. The Ulster Medical Journal, 83(2), 103–110.

    PubMed  PubMed Central  Google Scholar 

  4. Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., Abeni, D., Boyle, P., & Melchi, C. F. (2005). Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. European Journal of Cancer, 41(1), 28–44. https://doi.org/10.1016/j.ejca.2004.10.015

    Article  PubMed  Google Scholar 

  5. Lideikaite, A., Mozuraitiene, J., & Letautiene, S. (2017). Analysis of prognostic factors for melanoma patients. Acta medica Lituanica, 24(1), 25–34. https://doi.org/10.6001/actamedica.v24i1.3460

    Article  PubMed  PubMed Central  Google Scholar 

  6. Society, A. C. (2021). Cancer Facts & Figures, 2021.

    Google Scholar 

  7. Moyers, J. T., Patel, A., Shih, W., & Nagaraj, G. (2020). Association of sociodemographic factors with immunotherapy receipt for metastatic melanoma in the US. JAMA Network Open, 3(9), e2015656. https://doi.org/10.1001/jamanetworkopen.2020.15656

    Article  PubMed  PubMed Central  Google Scholar 

  8. Govindarajan, B., Bai, X., Cohen, C., Zhong, H., Kilroy, S., Louis, G., Moses, M., & Arbiser, J. L. (2003). Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. Journal of Biological Chemistry, 278(11), 9790–9795. https://doi.org/10.1074/jbc.M212929200

    Article  CAS  Google Scholar 

  9. Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., van Belle, P., Elder, D. E., & Herlyn, M. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Research, 63(4), 756.

    CAS  PubMed  Google Scholar 

  10. Genomic Classification of Cutaneous Melanoma. (2015). Cell, 161(7), 1681–1696. https://doi.org/10.1016/j.cell.2015.05.044.

  11. Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., Chiarion-Sileni, V., Lebbe, C., Mandala, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B., Hansson, J., Utikal, J., Ferraresi, V., Kovalenko, N., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., DeMarini, D. J., Irani, J. G., Swann, S., Legos, J. J., Jin, F., Mookerjee, B., & Flaherty, K. (2015). Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet, 386(9992), 444–451. https://doi.org/10.1016/s0140-6736(15)60898-4

    Article  CAS  PubMed  Google Scholar 

  12. Larkin, J., Ascierto, P. A., Dreno, B., Atkinson, V., Liszkay, G., Maio, M., Mandala, M., Demidov, L., Stroyakovskiy, D., Thomas, L., de la Cruz-Merino, L., Dutriaux, C., Garbe, C., Sovak, M. A., Chang, I., Choong, N., Hack, S. P., McArthur, G. A., & Ribas, A. (2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. The New England Journal of Medicine, 371(20), 1867–1876. https://doi.org/10.1056/NEJMoa1408868

    Article  CAS  PubMed  Google Scholar 

  13. McArthur, G. A. D. B., & Larkin, J., et al. (2019). 5-year survival update of cobimetinib plus vemurafenib BRAF V600 mutation-positive advanced melanoma: Final analysis of the coBRIM study. In the 16th International Congress of the Society for Melanoma Research, Salt Lake City, UT.

    Google Scholar 

  14. Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J. W. B., Yamazaki, N., Loquai, C., Moutouh-de Parseval, L. A., Pickard, M. D., Sandor, V., Robert, C., & Flaherty, K. T. (2018). Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 19(10), 1315–1327. https://doi.org/10.1016/s1470-2045(18)30497-2

    Article  CAS  PubMed  Google Scholar 

  15. Ascierto, P. A., Dummer, R., Gogas, H. J., Flaherty, K. T., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., de Groot, J. W. B., Loquai, C., Gollerkeri, A., Pickard, M. D., & Robert, C. (2020). Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. European Journal of Cancer, 126, 33–44. https://doi.org/10.1016/j.ejca.2019.11.016

    Article  CAS  PubMed  Google Scholar 

  16. Jiang, T., Zhou, C., & Ren, S. (2016). Role of IL-2 in cancer immunotherapy. Oncoimmunology, 5(6), e1163462. https://doi.org/10.1080/2162402x.2016.1163462

    Article  PubMed  PubMed Central  Google Scholar 

  17. Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., Paradise, C., Kunkel, L., & Rosenberg, S. A. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology, 17(7), 2105–2116.

    Article  CAS  Google Scholar 

  18. Hughes, T., Klairmont, M., Broucek, J., Iodice, G., Basu, S., & Kaufman, H. L. (2015). The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunology, Immunotherapy, 64(4), 459–465. https://doi.org/10.1007/s00262-014-1652-6

    Article  CAS  PubMed  Google Scholar 

  19. Schwartzentruber, D. J. (2001). Guidelines for the safe administration of high-dose interleukin-2. Journal of Immunotherapy, 24(4), 287–293.

    Article  CAS  Google Scholar 

  20. Buchbinder, E. I., Gunturi, A., Perritt, J., Dutcher, J., Aung, S., Kaufman, H. L., Ernstoff, M. S., Miletello, G. P., Curti, B. D., Daniels, G. A., Patel, S. P., Kirkwood, J. M., Hallmeyer, S., Clark, J. I., Gonzalez, R., Richart, J. M., Lutzky, J., Morse, M. A., Sullivan, R. J., & McDermott, D. F. (2016). A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. Journal for Immunotherapy of Cancer, 4, 52. https://doi.org/10.1186/s40425-016-0155-8

    Article  PubMed  PubMed Central  Google Scholar 

  21. Buchbinder, E. I., Dutcher, J. P., Daniels, G. A., Curti, B. D., Patel, S. P., Holtan, S. G., Miletello, G. P., Fishman, M. N., Gonzalez, R., Clark, J. I., Richart, J. M., Lao, C. D., Tykodi, S. S., Silk, A. W., & McDermott, D. F. (2019). Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. Journal for Immunotherapy of Cancer, 7(1), 49. https://doi.org/10.1186/s40425-019-0522-3

    Article  PubMed  PubMed Central  Google Scholar 

  22. Serrone, L., Zeuli, M., Sega, F. M., & Cognetti, F. (2000). Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. Journal of Experimental & Clinical Cancer Research, 19(1), 21–34.

    CAS  Google Scholar 

  23. Hill, G. J., 2nd, Krementz, E. T., & Hill, H. Z. (1984). Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer, 53(6), 1299–1305.

    Article  Google Scholar 

  24. Bajetta, E., Del Vecchio, M., Bernard-Marty, C., Vitali, M., Buzzoni, R., Rixe, O., Nova, P., Aglione, S., Taillibert, S., & Khayat, D. (2002). Metastatic melanoma: Chemotherapy. Seminars in Oncology, 29(5), 427–445.

    Article  CAS  Google Scholar 

  25. Bhatia, S., Tykodi, S. S., & Thompson, J. A. (2009). Treatment of metastatic melanoma: An Overview. Oncology (Williston Park), 23(6), 488–496.

    Google Scholar 

  26. Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., Dreno, B., Henz, M., Schadendorf, D., Kapp, A., Weiss, J., Fraass, U., Statkevich, P., Muller, M., & Thatcher, N. (2000). Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology, 18(1), 158–166. https://doi.org/10.1200/jco.2000.18.1.158

    Article  CAS  PubMed  Google Scholar 

  27. Li, R. H., Hou, X. Y., Yang, C. S., Liu, W. L., Tang, J. Q., Liu, Y. Q., & Jiang, G. (2015). Temozolomide for treating malignant melanoma. Journal of the College of Physicians and Surgeons – Pakistan: JCPSP, 25(9), 680–688. PMID: 26374366.

    Google Scholar 

  28. Quirt, I., Verma, S., Petrella, T., Bak, K., & Charette, M. (2007). Temozolomide for the treatment of metastatic melanoma: A systematic review. The Oncologist, 12(9), 1114–1123. https://doi.org/10.1634/theoncologist.12-9-1114

    Article  CAS  PubMed  Google Scholar 

  29. Kim, K. B., Papadopoulos, N., Bedikian, A. Y., DeConti, R. C., Conry, R., Agarwala, S., & Ernstoff, M. (2010). Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Annals of Oncology, 22(4), 787–793. https://doi.org/10.1093/annonc/mdq438

    Article  PubMed  PubMed Central  Google Scholar 

  30. Hersh, E. M., O'Day, S. J., Ribas, A., Samlowski, W. E., Gordon, M. S., Shechter, D. E., Clawson, A. A., & Gonzalez, R. (2010). A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer, 116(1), 155–163. https://doi.org/10.1002/cncr.24720

    Article  CAS  PubMed  Google Scholar 

  31. Hodi, F. S., Soiffer, R. J., Clark, J., Finkelstein, D. M., & Haluska, F. G. (2002). Phase II study of paclitaxel and carboplatin for malignant melanoma. American Journal of Clinical Oncology, 25(3), 283–286.

    Article  Google Scholar 

  32. Rao, R. D., Holtan, S. G., Ingle, J. N., Croghan, G. A., Kottschade, L. A., Creagan, E. T., Kaur, J. S., Pitot, H. C., & Markovic, S. N. (2006). Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer, 106(2), 375–382. https://doi.org/10.1002/cncr.21611

    Article  CAS  PubMed  Google Scholar 

  33. Kottschade, L. A., Suman, V. J., Amatruda, T., 3rd, McWilliams, R. R., Mattar, B. I., Nikcevich, D. A., Behrens, R., Fitch, T. R., Jaslowski, A. J., & Markovic, S. N. (2011). A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group Study, N057E(1). Cancer, 117(8), 1704–1710. https://doi.org/10.1002/cncr.25659

    Article  CAS  PubMed  Google Scholar 

  34. Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L., Kefford, R., Atkins, M. B., Leming, P., & Kirkwood, J. M. (2013). Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31(3), 373–379. https://doi.org/10.1200/JCO.2012.42.1529

    Article  CAS  Google Scholar 

  35. Legha, S. S., Ring, S., Papadopoulos, N., Plager, C., Chawla, S., & Benjamin, R. (1989). A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer, 64(10), 2024–2029.

    Article  CAS  Google Scholar 

  36. Atkins, M. B., Hsu, J., Lee, S., Cohen, G. I., Flaherty, L. E., Sosman, J. A., Sondak, V. K., & Kirkwood, J. M. (2008). Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 26(35), 5748–5754. https://doi.org/10.1200/jco.2008.17.5448

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ludford, K., Johnson, D. H., Hennegan, T., Gruschkus, S. K., Haymaker, C. L., Bernatchez, C., Jackson, N., Hwu, P., & Diab, A. (2019). Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma. Journal of Clinical Oncology, 37(15_suppl), 9554. https://doi.org/10.1200/JCO.2019.37.15_suppl.9554

    Article  Google Scholar 

  38. Jamal, R., Lapointe, R., Cocolakis, E., Thébault, P., Kazemi, S., Friedmann, J. E., Dionne, J., Cailhier, J. F., Bélanger, K., Ayoub, J. P., Le, H., Lambert, C., El-Hajjar, J., van Kempen, L. C., Spatz, A., & Miller, W. H., Jr. (2017). Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Journal for Immunotherapy of Cancer, 5(1), 83. https://doi.org/10.1186/s40425-017-0290-x

    Article  PubMed  PubMed Central  Google Scholar 

  39. Grunhagen, D. J., & Verhoef, C. (2016). Isolated limb perfusion for stage III melanoma: Does it still have a role in the present era of effective systemic therapy? Oncology (Williston Park), 30(12), 1045–1052.

    Google Scholar 

  40. Miura, J. T., Kroon, H. M., Beasley, G. M., Mullen, D., Farrow, N. E., Mosca, P. J., Lowe, M. C., Farley, C. R., Kim, Y., Naqvi, S. M. H., Potdar, A., Daou, H., Sun, J., Farma, J. M., Henderson, M. A., Speakman, D., Serpell, J., Delman, K. A., Mark Smithers, B., Coventry, B. J., Tyler, D. S., Thompson, J. F., & Zager, J. S. (2019). Long-term oncologic outcomes after isolated limb infusion for locoregionally metastatic melanoma: An international multicenter analysis. Annals of Surgical Oncology, 26(8), 2486–2494. https://doi.org/10.1245/s10434-019-07288-w

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lotze, M. T., & Rosenberg, S. A. (1986). Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology, 172(3–5), 420–437. https://doi.org/10.1016/s0171-2985(86)80122-x

    Article  CAS  PubMed  Google Scholar 

  42. Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., & White, D. E. (1994). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Journal of the National Cancer Institute, 86(15), 1159–1166.

    Article  CAS  Google Scholar 

  43. Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., Rogers, L. J., Gracia, G. J., Jones, S. A., Mangiameli, D. P., Pelletier, M. M., Gea-Banacloche, J., Robinson, M. R., Berman, D. M., Filie, A. C., Abati, A., & Rosenberg, S. A. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology, 23(10), 2346–2357. https://doi.org/10.1200/jco.2005.00.240

    Article  CAS  PubMed  Google Scholar 

  44. Dafni, U., Michielin, O., Lluesma, S. M., Tsourti, Z., Polydoropoulou, V., Karlis, D., Besser, M. J., Haanen, J., Svane, I. M., Ohashi, P. S., Kammula, U. S., Orcurto, A., Zimmermann, S., Trueb, L., Klebanoff, C. A., Lotze, M. T., Kandalaft, L. E., & Coukos, G. (2019). Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: A systematic review and meta-analysis. Annals of Oncology, 30(12), 1902–1913. https://doi.org/10.1093/annonc/mdz398

    Article  CAS  PubMed  Google Scholar 

  45. Baruch, E. N., Berg, A. L., Besser, M. J., Schachter, J., & Markel, G. (2017). Adoptive T cell therapy: An overview of obstacles and opportunities. Cancer, 123(S11), 2154–2162. https://doi.org/10.1002/cncr.30491

    Article  PubMed  Google Scholar 

  46. Merhavi-Shoham, E., Itzhaki, O., Markel, G., Schachter, J., & Besser, M. J. (2017). Adoptive cell therapy for metastatic melanoma. Cancer Journal, 23(1), 48–53. https://doi.org/10.1097/ppo.0000000000000240

    Article  CAS  Google Scholar 

  47. Page, D. M., Kane, L. P., Allison, J. P., & Hedrick, S. M. (1993). Two signals are required for negative selection of CD4+CD8+ thymocytes. Journal of Immunology, 151(4), 1868–1880.

    CAS  Google Scholar 

  48. Brunet, J. F., Dosseto, M., Denizot, F., Mattei, M. G., Clark, W. R., Haqqi, T. M., Ferrier, P., Nabholz, M., Schmitt-Verhulst, A. M., Luciani, M. F., & Golstein, P. (1986). The inducible cytotoxic T-lymphocyte-associated gene transcript CTLA-1 sequence and gene localization to mouse chromosome 14. Nature, 322(6076), 268–271. https://doi.org/10.1038/322268a0

    Article  CAS  PubMed  Google Scholar 

  49. Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe'er, D., & Allison, J. P. (2017). Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell, 170(6), 1120–1133.e1117. https://doi.org/10.1016/j.cell.2017.07.024

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbe, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., & Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711–723. https://doi.org/10.1056/NEJMoa1003466

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Robert, C., Thomas, L., Bondarenko, I., O’Day, S. M. D. J., Garbe, C., Lebbe, C., Baurain, J. F., Testori, A., Grob, J. J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H., Jr., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T. T., Humphrey, R., Hoos, A., & Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine, 364(26), 2517–2526. https://doi.org/10.1056/NEJMoa1104621

    Article  CAS  PubMed  Google Scholar 

  52. Olson, D., Luke, J. J., Poklepovic, A. S., Bajaj, M., Higgs, E., Carll, T. C., Labadie, B., Krausz, T., Zha, Y., Karrison, T., Lutzky, J., Hallmeyer, S., Brockstein, B., Sondak, V. K., Eroglu, Z., Gajewski, T., & Khushalani, N. I. (2020). Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial. Journal of Clinical Oncology, 38(15_suppl), 10004. https://doi.org/10.1200/JCO.2020.38.15_suppl.10004

    Article  Google Scholar 

  53. Silva, I. P. D., Ahmed, T., Lo, S., Reijers, I. L. M., Weppler, A., Warner, A. B., Patrinely, J. R., Serra-Bellver, P., Lebbe, C., Mangana, J., Nguyen, K., Zimmer, L., Ascierto, P. A., Stout, D., Lyle, M., Klein, O., Gerard, C. L., Blank, C. U., Menzies, A. M., & Long, G. V. (2020). Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. Journal of Clinical Oncology, 38(15_suppl), 10005. https://doi.org/10.1200/JCO.2020.38.15_suppl.10005

    Article  Google Scholar 

  54. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer, 12(4), 252–264. https://doi.org/10.1038/nrc3239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015). Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine, 21(1), 24–33. https://doi.org/10.1016/j.molmed.2014.10.009

    Article  CAS  PubMed  Google Scholar 

  56. Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017). Monitoring immune-checkpoint blockade: Response evaluation and biomarker development. Nature Reviews. Clinical Oncology, 14(11), 655–668. https://doi.org/10.1038/nrclinonc.2017.88

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbe, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I. M., Atkinson, V., & Ascierto, P. A. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. The New England Journal of Medicine, 372(4), 320–330. https://doi.org/10.1056/NEJMoa1412082

    Article  CAS  PubMed  Google Scholar 

  58. Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Ny, L., Arance, A., Svane, I. M., Schadendorf, D., Gogas, H., Saci, A., Jiang, J., Rizzo, J., & Atkinson, V. (2019). Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: Three-year follow-up of a randomized phase 3 trial. JAMA Oncology, 5(2), 187–194. https://doi.org/10.1001/jamaoncol.2018.4514

    Article  PubMed  Google Scholar 

  59. Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., Bello, A., Roy, A., & Agrawal, S. (2017). Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Annals of Oncology, 28(8), 2002–2008. https://doi.org/10.1093/annonc/mdx235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Long, G. V., Tykodi, S. S., Schneider, J. G., Garbe, C., Gravis, G., Rashford, M., Agrawal, S., Grigoryeva, E., Bello, A., Roy, A., Rollin, L., & Zhao, X. (2018). Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Annals of Oncology, 29(11), 2208–2213. https://doi.org/10.1093/annonc/mdy408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., Cranmer, L. D., Blank, C. U., O'Day, S. J., Ascierto, P. A., Salama, A. K., Margolin, K. A., Loquai, C., Eigentler, T. K., Gangadhar, T. C., Carlino, M. S., Agarwala, S. S., Moschos, S. J., Sosman, J. A., Goldinger, S. M., Shapira-Frommer, R., Gonzalez, R., Kirkwood, J. M., Wolchok, J. D., Eggermont, A., Li, X. N., Zhou, W., Zernhelt, A. M., Lis, J., Ebbinghaus, S., Kang, S. P., & Daud, A. (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. The Lancet Oncology, 16(8), 908–918. https://doi.org/10.1016/s1470-2045(15)00083-2

    Article  CAS  PubMed  Google Scholar 

  62. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., & Ribas, A. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. The New England Journal of Medicine, 372(26), 2521–2532. https://doi.org/10.1056/NEJMoa1503093

    Article  CAS  PubMed  Google Scholar 

  63. Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., Larkin, J. M. G., Lorigan, P., Neyns, B., Blank, C. U., Petrella, T. M., Hamid, O., Su, S.-C., Krepler, C., Ibrahim, N., & Long, G. V. (2019). Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet Oncology, 20(9), 1239–1251. https://doi.org/10.1016/S1470-2045(19)30388-2

    Article  CAS  PubMed  Google Scholar 

  64. Freshwater, T., Kondic, A., Ahamadi, M., Li, C. H., de Greef, R., de Alwis, D., & Stone, J. A. (2017). Evaluation of dosing strategy for pembrolizumab for oncology indications. Journal for Immunotherapy of Cancer, 5(1), 43. https://doi.org/10.1186/s40425-017-0242-5

    Article  PubMed  PubMed Central  Google Scholar 

  65. Lala, M., Li, T. R., de Alwis, D. P., Sinha, V., Mayawala, K., Yamamoto, N., Siu, L. L., Chartash, E., Aboshady, H., & Jain, L. (2020). A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. European Journal of Cancer, 131, 68–75. https://doi.org/10.1016/j.ejca.2020.02.016

    Article  CAS  PubMed  Google Scholar 

  66. Naing, A., Gainor, J. F., Gelderblom, H., Forde, P. M., Butler, M. O., Lin, C. C., Sharma, S., Ochoa de Olza, M., Varga, A., Taylor, M., Schellens, J. H. M., Wu, H., Sun, H., Silva, A. P., Faris, J., Mataraza, J., Cameron, S., & Bauer, T. M. (2020). A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. Journal for Immunotherapy of Cancer, 8(1). https://doi.org/10.1136/jitc-2020-000530

  67. Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, W. M. D., Forde, P., Sarantopoulos, J., Bedard, P. L., Lin, C.-C., Hodi, S., Wilgenhof, S., Santoro, A., Sabatos-Peyton, C., Longmire, T., Wan, K., Nikolopoulos, P., Manenti, L., & Naing, A. (2019). Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies. Cancer Research, 79(13 Supplement), CT183–CT183. https://doi.org/10.1158/1538-7445.Am2019-ct183

    Article  Google Scholar 

  68. Keam, S. J. (2019). Toripalimab: First global approval. Drugs, 79(5), 573–578. https://doi.org/10.1007/s40265-019-01076-2

    Article  CAS  PubMed  Google Scholar 

  69. Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., LIAN, B., Wang, X., Bai, X., Zhou, L., Kong, Y., Dai, J., Flaherty, K., Guo, J., & Biosciences, S. J. (2020). Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma. Journal of Clinical Oncology, 38(15_suppl), 10007. https://doi.org/10.1200/JCO.2020.38.15_suppl.10007

    Article  Google Scholar 

  70. Hodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D. R., Salama, A. K., Taylor, M. H., Ott, P. A., Horak, C., Gagnier, P., Jiang, J., Wolchok, J. D., & Postow, M. A. (2016). Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology, 17(11), 1558–1568. https://doi.org/10.1016/s1470-2045(16)30366-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Larkin, J., Hodi, F. S., & Wolchok, J. D. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine, 373(13), 1270–1271. https://doi.org/10.1056/NEJMc1509660

    Article  PubMed  Google Scholar 

  72. Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., de Braud, F., Chau, I., Harbison, C. T., Dorange, C., Tschaika, M., & Le, D. T. (2018). CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. Journal of Clinical Oncology, 36(28), 2836–2844. https://doi.org/10.1200/jco.2017.76.6212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M. O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., & Escudier, B. (2018). Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. The New England Journal of Medicine, 378(14), 1277–1290. https://doi.org/10.1056/NEJMoa1712126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Hellmann, M. D., Ciuleanu, T. E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., Borghaei, H., Ramalingam, S. S., Brahmer, J., Reck, M., O'Byrne, K. J., Geese, W. J., Green, G., Chang, H., Szustakowski, J., Bhagavatheeswaran, P., Healey, D., Fu, Y., Nathan, F., & Paz-Ares, L. (2018). Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. The New England Journal of Medicine, 378(22), 2093–2104. https://doi.org/10.1056/NEJMoa1801946

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., Schadendorf, D., Ajaz, M., Svane, I. M., Gonzalez, R., Rollin, L., Lord-Bessen, J., Saci, A., Grigoryeva, E., & Pigozzo, J. (2019). Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: Results from the phase IIIb/IV CheckMate 511 trial. Journal of Clinical Oncology, 37(11), 867–875. https://doi.org/10.1200/JCO.18.01998

    Article  PubMed  PubMed Central  Google Scholar 

  76. Long, G. V., Atkinson, V., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., Hwu, W. J., Hodi, F. S., Menzies, A. M., Guminski, A. D., Kefford, R., Kong, B. Y., Tamjid, B., Srivastava, A., Lomax, A. J., Islam, M., Shu, X., Ebbinghaus, S., Ibrahim, N., & Carlino, M. S. (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): An open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202–1210. https://doi.org/10.1016/s1470-2045(17)30428-x

    Article  CAS  PubMed  Google Scholar 

  77. Cohen, J. V., Tawbi, H., Margolin, K. A., Amravadi, R., Bosenberg, M., Brastianos, P. K., Chiang, V. L., de Groot, J., Glitza, I. C., Herlyn, M., Holmen, S. L., Jilaveanu, L. B., Lassman, A., Moschos, S., Postow, M. A., Thomas, R., Tsiouris, J. A., Wen, P., White, R. M., Turnham, T., Davies, M. A., & Kluger, H. M. (2016). Melanoma central nervous system metastases: Current approaches, challenges, and opportunities. Pigment Cell & Melanoma Research, 29(6), 627–642. https://doi.org/10.1111/pcmr.12538

    Article  Google Scholar 

  78. Kluger, H. M., Chiang, V., Mahajan, A., Zito, C. R., Sznol, M., Tran, T., Weiss, S. A., Cohen, J. V., Yu, J., Hegde, U., Perrotti, E., Anderson, G., Ralabate, A., Kluger, Y., Wei, W., Goldberg, S. B., & Jilaveanu, L. B. (2019). Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. Journal of Clinical Oncology, 37(1), 52–60. https://doi.org/10.1200/jco.18.00204

    Article  CAS  PubMed  Google Scholar 

  79. Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., Richards, J., Michener, T., Balogh, A., Heller, K. N., & Hodi, F. S. (2012). Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. The Lancet Oncology, 13(5), 459–465. https://doi.org/10.1016/s1470-2045(12)70090-6

    Article  CAS  PubMed  Google Scholar 

  80. Goldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J., Vortmeyer, A., Jilaveanu, L., Yu, J., Hegde, U., Speaker, S., Madura, M., Ralabate, A., Rivera, A., Rowen, E., Gerrish, H., Yao, X., Chiang, V., & Kluger, H. M. (2016). Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial. The Lancet Oncology, 17(7), 976–983. https://doi.org/10.1016/s1470-2045(16)30053-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Tawbi, H. A.-H., Forsyth, P. A. J., Hodi, F. S., Lao, C. D., Moschos, S. J., Hamid, O., Atkins, M. B., Lewis, K. D., Thomas, R. P., Glaspy, J. A., Jang, S., Algazi, A. P., Khushalani, N. I., Postow, M. A., Pavlick, A. C., Ernstoff, M. S., Reardon, D. A., Balogh, A., Rizzo, J. I., & Margolin, K. A. (2019). Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). Journal of Clinical Oncology, 37(15_suppl), 9501. https://doi.org/10.1200/JCO.2019.37.15_suppl.9501

    Article  Google Scholar 

  82. Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., Atkins, M. B., Ernstoff, M. S., Reardon, D. A., Puzanov, I., Kudchadkar, R. R., Thomas, R. P., Tarhini, A., Pavlick, A. C., Jiang, J., Avila, A., Demelo, S., & Margolin, K. (2018). Combined nivolumab and ipilimumab in melanoma metastatic to the brain. New England Journal of Medicine, 379(8), 722–730. https://doi.org/10.1056/NEJMoa1805453

    Article  CAS  Google Scholar 

  83. Long, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., Wilmott, J. S., Edwards, J., Gonzalez, M., Scolyer, R. A., Menzies, A. M., & McArthur, G. A. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study. The Lancet Oncology, 19(5), 672–681. https://doi.org/10.1016/s1470-2045(18)30139-6

    Article  CAS  PubMed  Google Scholar 

  84. Glitza, I. C., Smalley, K. S. M., Brastianos, P. K., Davies, M. A., McCutcheon, I., Liu, J. K. C., Ahmed, K. A., Arrington, J. A., Evernden, B. R., Smalley, I., Eroglu, Z., Khushalani, N., Margolin, K., Kluger, H., Atkins, M. B., Tawbi, H., Boire, A., & Forsyth, P. (2020). Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell & Melanoma Research, 33(4), 527–541. https://doi.org/10.1111/pcmr.12861

    Article  Google Scholar 

  85. Glitza, I. C., Phillips, S., Brown, C., Haymaker, C. L., Bassett, R. L., Lee, J. J., Rohlfs, M. L., Richard, J., Iqbal, M., John, I., McCutcheon, I. E., Ferguson, S. D., Heimberger, A. B., O'Brien, B. J., Tummala, S., Thakurta, N. G., Debnam, M., Burton, E. M., Tawbi, H. A.-H., & Davies, M. A. (2020). Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). Journal of Clinical Oncology, 38(15_suppl), 10008. https://doi.org/10.1200/JCO.2020.38.15_suppl.10008

    Article  Google Scholar 

  86. Chen Daniel, S., & Mellman, I. (2013). Oncology meets immunology: The cancer-immunity cycle. Immunity, 39(1), 1–10. https://doi.org/10.1016/j.immuni.2013.07.012

    Article  CAS  PubMed  Google Scholar 

  87. De Sousa Linhares, A., Battin, C., Jutz, S., Leitner, J., Hafner, C., Tobias, J., Wiedermann, U., Kundi, M., Zlabinger, G. J., Grabmeier-Pfistershammer, K., & Steinberger, P. (2019). Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Scientific Reports, 9(1), 11472. https://doi.org/10.1038/s41598-019-47910-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Hamid, O., Sosman, J. A., Lawrence, D. P., Sullivan, R. J., Ibrahim, N., Kluger, H. M., Boasberg, P. D., Flaherty, K., Hwu, P., Ballinger, M., Mokatrin, A., Kowanetz, M., Chen, D. S., & Hodi, F. S. (2013). Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). Journal of Clinical Oncology, 31(15_suppl), 9010. https://doi.org/10.1200/jco.2013.31.15_suppl.9010

    Article  Google Scholar 

  89. Keilholz, U., Mehnert, J. M., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L., Lee, K.-W., Kasturi, V., Chin, K., von Heydebreck, A., & Gulley, J. L. (2019). Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial. Journal for Immunotherapy of Cancer, 7(1), 12. https://doi.org/10.1186/s40425-018-0459-y

    Article  PubMed  PubMed Central  Google Scholar 

  90. Ribas, A., Butler, M., Lutzky, J., Lawrence, D. P., Robert, C., Miller, W., Linette, G. P., Ascierto, P. A., Kuzel, T., Algazi, A. P., Postow, M. A., Nathan, P. D., Curti, B. D., Robbins, P. B., Li, X., Blake-Haskins, J. A., & Gordon, M. S. (2015). Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. Journal of Clinical Oncology, 33(15_suppl), 3003. https://doi.org/10.1200/jco.2015.33.15_suppl.3003

    Article  Google Scholar 

  91. Arance, A., Gogas, H., Dreno, B., Flaherty, K. T., Demidov, L., Stroyakovski, D., Eroglu, Z., Ferrucci, P. F., Pigozzo, J., Rutkowski, P., Mackiewicz, J., Rooney, I., Voulgari, A., Troutman, S., Pitcher, B., Yan, Y., & Larkin, J. M. G. (2019). Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase 3 IMspire170 trial. Annals of Oncology, 30(suppl_5), v851–v934.

    Google Scholar 

  92. Dummer, R., Lebbé, C., Atkinson, V., Mandalà, M., Nathan, P. D., Arance, A., Richtig, E., Yamazaki, N., Robert, C., Schadendorf, D., Tawbi, H. A., Ascierto, P. A., Ribas, A., Flaherty, K. T., Pakhle, N., Campbell, C. D., Gusenleitner, D., Masood, A., Brase, J. C., Gasal, E., & Long, G. V. (2020). Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: Safety run-in and biomarker cohorts of COMBI-i. Nature Medicine, 26(10), 1557–1563. https://doi.org/10.1038/s41591-020-1082-2

    Article  CAS  PubMed  Google Scholar 

  93. Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H., & Ribas, A. (2019). Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine, 25(6), 941–946. https://doi.org/10.1038/s41591-019-0448-9

    Article  CAS  PubMed  Google Scholar 

  94. Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., Manikhas, G. M., Yan, Y., Huang, K. C., Uyei, A., McNally, V., McArthur, G. A., & Ascierto, P. A. (2020). Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 395(10240), 1835–1844. https://doi.org/10.1016/s0140-6736(20)30934-x

    Article  CAS  PubMed  Google Scholar 

  95. Naing, A., Hajjar, J., Gulley, J. L., Atkins, M. B., Ciliberto, G., Meric-Bernstam, F., & Hwu, P. (2020). Strategies for improving the management of immune-related adverse events. Journal for Immunotherapy of Cancer, 8(2), e001754. https://doi.org/10.1136/jitc-2020-001754

    Article  PubMed  PubMed Central  Google Scholar 

  96. Cousin, S., Seneschal, J., & Italiano, A. (2018). Toxicity profiles of immunotherapy. Pharmacology & Therapeutics, 181, 91–100. https://doi.org/10.1016/j.pharmthera.2017.07.005

    Article  CAS  Google Scholar 

  97. Kanjanapan, Y., Day, D., Butler, M. O., Wang, L., Joshua, A. M., Hogg, D., Leighl, N. B., Razak, A. R. A., Hansen, A. R., Boujos, S., Chappell, M., Chow, K., Sherwin, B., Stayner, L. A., Soultani, L., Zambrana, A., Siu, L. L., Bedard, P. L., & Spreafico, A. (2019). Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. European Journal of Cancer, 107, 1–7. https://doi.org/10.1016/j.ejca.2018.10.017

    Article  CAS  PubMed  Google Scholar 

  98. Abu-Sbeih, H., Ali, F. S., Qiao, W., Lu, Y., Patel, S., Diab, A., & Wang, Y. (2019). Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunology, Immunotherapy, 68(4), 553–561. https://doi.org/10.1007/s00262-019-02303-1

    Article  CAS  PubMed  Google Scholar 

  99. Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P. C., Krepler, C., Ibrahim, N., Marreaud, S., van Akkooi, A., Robert, C., & Suciu, S. (2020). Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial. JAMA Oncology, 6(4), 519–527. https://doi.org/10.1001/jamaoncol.2019.5570

    Article  PubMed  PubMed Central  Google Scholar 

  100. Fujii, T., Colen, R. R., Bilen, M. A., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Tsimberidou, A., Janku, F., Gong, J., Stephen, B., Subbiah, V., Piha-Paul, S. A., Fu, S., Sharma, P., Mendoza, T., Patel, A., Thirumurthi, S., Sheshadri, A., Meric-Bernstam, F., & Naing, A. (2018). Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience. Investigational New Drugs, 36(4), 638–646. https://doi.org/10.1007/s10637-017-0534-0

    Article  CAS  PubMed  Google Scholar 

  101. Dolladille, C., Ederhy, S., Sassier, M., Cautela, J., Thuny, F., Cohen, A. A., Fedrizzi, S., Chrétien, B., Da-Silva, A., Plane, A.-F., Legallois, D., Milliez, P. U., Lelong-Boulouard, V., & Alexandre, J. (2020). Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncology, 6(6), 865–871. https://doi.org/10.1001/jamaoncol.2020.0726

    Article  PubMed  Google Scholar 

  102. Allouchery, M., Lombard, T., Martin, M., Rouby, F., Sassier, M., Bertin, C., Atzenhoffer, M., Miremont-Salame, G., Perault-Pochat, M.-C., & Puyade, M. (2020). Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. Journal for Immunotherapy of Cancer, 8(2), e001622. https://doi.org/10.1136/jitc-2020-001622

    Article  PubMed  PubMed Central  Google Scholar 

  103. Hirayama, M., & Nishimura, Y. (2016). The present status and future prospects of peptide-based cancer vaccines. International Immunology, 28(7), 319–328. https://doi.org/10.1093/intimm/dxw027

    Article  CAS  PubMed  Google Scholar 

  104. Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., Kendra, K. L., White, R. L., Gonzalez, R., Kuzel, T. M., Curti, B., Leming, P. D., Whitman, E. D., Balkissoon, J., Reintgen, D. S., Kaufman, H., Marincola, F. M., Merino, M. J., Rosenberg, S. A., Choyke, P., Vena, D., & Hwu, P. (2011). gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England Journal of Medicine, 364(22), 2119–2127. https://doi.org/10.1056/NEJMoa1012863

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., Friedlander, T., Bushway, M. E., Balogh, K. N., Sciuto, T. E., Kohler, V., Turnbull, S. J., Besada, R., Curran, R. R., Trapp, B., Scherer, J., Poran, A., Harjanto, D., Barthelme, D., Ting, Y. S., Dong, J. Z., Ware, Y., Huang, Y., Huang, Z., Wanamaker, A., Cleary, L. D., Moles, M. A., Manson, K., Greshock, J., Khondker, Z. S., Fritsch, E., Rooney, M. S., DeMario, M., Gaynor, R. B., & Srinivasan, L. (2020). A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell, 183(2), 347–362.e324. https://doi.org/10.1016/j.cell.2020.08.053

    Article  CAS  PubMed  Google Scholar 

  106. Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018). Talimogene laherparepvec: First in class oncolytic virotherapy. Human Vaccines & Immunotherapeutics, 14(4), 839–846. https://doi.org/10.1080/21645515.2017.1412896

    Article  Google Scholar 

  107. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G. P., Daniels, G. A., Harrington, K., Middleton, M. R., Miller, W. H., Jr., Zager, J. S., Ye, Y., Yao, B., Li, A., Doleman, S., VanderWalde, A., Gansert, J., & Coffin, R. S. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology, 33(25), 2780–2788. https://doi.org/10.1200/jco.2014.58.3377

    Article  CAS  PubMed  Google Scholar 

  108. Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., Kaufman, H. L., & Andtbacka, R. H. (2016). Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. Journal of Clinical Oncology, 34(22), 2619–2626. https://doi.org/10.1200/jco.2016.67.1529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., Kirkwood, J. M., Gajewski, T. F., Chen, L., Gorski, K. S., Anderson, A. A., Diede, S. J., Lassman, M. E., Gansert, J., Hodi, F. S., & Long, G. V. (2017). Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell, 170(6), 1109–1119.e1110. https://doi.org/10.1016/j.cell.2017.08.027

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Thompson, J. F., Hersey, P., & Wachter, E. (2008). Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Research, 18(6), 405–411. https://doi.org/10.1097/CMR.0b013e32831328c7

    Article  PubMed  Google Scholar 

  111. Thompson, J. F., Agarwala, S. S., Smithers, B. M., Ross, M. I., Scoggins, C. R., Coventry, B. J., Neuhaus, S. J., Minor, D. R., Singer, J. M., & Wachter, E. A. (2015). Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Annals of Surgical Oncology, 22(7), 2135–2142. https://doi.org/10.1245/s10434-014-4169-5

    Article  PubMed  Google Scholar 

  112. Read, T. A., Smith, A., Thomas, J., David, M., Foote, M., Wagels, M., Barbour, A., & Smithers, B. M. (2018). Intralesional PV-10 for the treatment of in-transit melanoma metastases-results of a prospective, non-randomized, single center study. Journal of Surgical Oncology, 117(4), 579–587. https://doi.org/10.1002/jso.24921

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Agarwala, S. S., Ross, M. I., Zager, J. S., Shirai, K., Essner, R., Smithers, B. M., Atkinson, V., & Wachter, E. A. (2019). Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma. Journal of Clinical Oncology, 37(15_suppl), 9559. https://doi.org/10.1200/JCO.2019.37.15_suppl.9559

    Article  Google Scholar 

  114. Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., & Xiong, H. (2008). TLR signaling by tumor and immune cells: A double-edged sword. Oncogene, 27(2), 218–224. https://doi.org/10.1038/sj.onc.1210904

    Article  CAS  PubMed  Google Scholar 

  115. Babiker, H. M., Subbiah, V., Ali, A., Algazi, A., Schachter, J., Lotem, M., Maurice-Dror, C., Hendler, D., Rahimian, S., Minderman, H., Haymaker, C., Bernatchez, C., Murthy, R., Hultsch, R., Caplan, N., Woodhead, G., Hennemeyer, C., Chunduru, S., Anderson, P., Diab, A., Borazanci, E., & Puzanov, I. (2020). Abstract CT134: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type-I IFN signaling in solid tumors. Cancer Research, 80(16 Supplement), CT134–CT134. https://doi.org/10.1158/1538-7445.Am2020-ct134

    Article  Google Scholar 

  116. Haymaker, C., Andtbacka, R. H. I., Johnson, D. B., Shaheen, M. F., Rahimian, S., Chunduru, S., Gabrail, N., Doolittle, G., Puzanov, I., Markowitz, J., Bernatchez, C., & Diab, A. (2020). 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma. Annals of Oncology, 31, S736. https://doi.org/10.1016/j.annonc.2020.08.1207

    Article  Google Scholar 

  117. Milhem, M., Gonzales, R., Medina, T., Kirkwood, J. M., Buchbinder, E., Mehmi, I., Niu, J., Shaheen, M., Weight, R., Margolin, K., Luke, J., Morris, A., Mauro, D., Krieg, A. M., & Ribas, A. (2018). Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma. Cancer Research, 78(13 Supplement), CT144. https://doi.org/10.1158/1538-7445.AM2018-CT144

    Article  Google Scholar 

  118. Milhem, M., Zakharia, Y., Davar, D., Buchbinder, E., Medina, T., Daud, A., Ribas, A., Niu, J., Gibney, G., & Margolin, K. (2020). 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. BMJ Specialist Journals.

    Google Scholar 

  119. Ribas, A., Medina, T., Kummar, S., Amin, A., Kalbasi, A., Drabick, J. J., Barve, M., Daniels, G. A., Wong, D. J., Schmidt, E. V., Candia, A. F., Coffman, R. L., Leung, A. C. F., & Janssen, R. S. (2018). SD-101 in combination with pembrolizumab in advanced melanoma: Results of a phase Ib, multicenter study. Cancer Discovery, 8(10), 1250–1257. https://doi.org/10.1158/2159-8290.Cd-18-0280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Balch, C. M., Gershenwald, J. E., Soong, S. J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., Eggermont, A. M., Flaherty, K. T., Gimotty, P. A., Kirkwood, J. M., McMasters, K. M., Mihm, M. C., Jr., Morton, D. L., Ross, M. I., Sober, A. J., & Sondak, V. K. (2009). Final version of 2009 AJCC melanoma staging and classification. Journal of Clinical Oncology, 27(36), 6199–6206. https://doi.org/10.1200/jco.2009.23.4799

    Article  PubMed  PubMed Central  Google Scholar 

  121. Gershenwald, J. E., & Scolyer, R. A. (2018). Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Annals of Surgical Oncology, 25(8), 2105–2110. https://doi.org/10.1245/s10434-018-6513-7

    Article  PubMed  Google Scholar 

  122. Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., Hoekstra, H. J., Moncrieff, M., Ingvar, C., Wouters, M. W. J. M., Sabel, M. S., Levine, E. A., Agnese, D., Henderson, M., Dummer, R., Rossi, C. R., Neves, R. I., Trocha, S. D., Wright, F., Byrd, D. R., Matter, M., Hsueh, E., MacKenzie-Ross, A., Johnson, D. B., Terheyden, P., Berger, A. C., Huston, T. L., Wayne, J. D., Smithers, B. M., Neuman, H. B., Schneebaum, S., Gershenwald, J. E., Ariyan, C. E., Desai, D. C., Jacobs, L., McMasters, K. M., Gesierich, A., Hersey, P., Bines, S. D., Kane, J. M., Barth, R. J., McKinnon, G., Farma, J. M., Schultz, E., Vidal-Sicart, S., Hoefer, R. A., Lewis, J. M., Scheri, R., Kelley, M. C., Nieweg, O. E., Noyes, R. D., Hoon, D. S. B., Wang, H.-J., Elashoff, D. A., & Elashoff, R. M. (2017). Completion dissection or observation for sentinel-node metastasis in melanoma. New England Journal of Medicine, 376(23), 2211–2222. https://doi.org/10.1056/NEJMoa1613210

    Article  Google Scholar 

  123. Agha, A., & Tarhini, A. A. (2017). Adjuvant therapy for melanoma. Current Oncology Reports, 19(5), 36. https://doi.org/10.1007/s11912-017-0594-5

    Article  CAS  PubMed  Google Scholar 

  124. Kirkwood, J. M., Resnick, G. D., & Cole, B. F. (1997). Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Seminars in Oncology, 24(1 Suppl 4), S16–S23.

    CAS  PubMed  Google Scholar 

  125. Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000). High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. Journal of Clinical Oncology, 18(12), 2444–2458. https://doi.org/10.1200/jco.2000.18.12.2444

    Article  CAS  PubMed  Google Scholar 

  126. Kirkwood, J. M., Manola, J., Ibrahim, J., Sondak, V., Ernstoff, M. S., & Rao, U. (2004). A pooled analysis of Eastern Cooperative Oncology Group and Intergroup Trials of adjuvant high-dose interferon for melanoma. Clinical Cancer Research, 10(5), 1670–1677. https://doi.org/10.1158/1078-0432.Ccr-1103-3

    Article  CAS  PubMed  Google Scholar 

  127. Flaherty, L. E., Othus, M., Atkins, M. B., Tuthill, R. J., Thompson, J. A., Vetto, J. T., Haluska, F. G., Pappo, A. S., Sosman, J. A., Redman, B. G., Moon, J., Ribas, A., Kirkwood, J. M., & Sondak, V. K. (2014). Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children’s Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Journal of Clinical Oncology, 32(33), 3771–3778. https://doi.org/10.1200/jco.2013.53.1590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Eggermont, A. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Konto, C., Hoos, A., de Pril, V., Gurunath, R. K., de Schaetzen, G., Suciu, S., & Testori, A. (2015). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. The Lancet Oncology, 16(5), 522–530. https://doi.org/10.1016/s1470-2045(15)70122-1

    Article  CAS  PubMed  Google Scholar 

  129. Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., Pril, V., Kicinski, M., Suciu, S., & Testori, A. (2019). Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. Journal of Clinical Oncology, 37(15_suppl), 2512. https://doi.org/10.1200/JCO.2019.37.15_suppl.2512

    Article  Google Scholar 

  130. Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J. J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbe, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J., & Ascierto, P. A. (2017). Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. The New England Journal of Medicine, 377(19), 1824–1835. https://doi.org/10.1056/NEJMoa1709030

    Article  CAS  PubMed  Google Scholar 

  131. Ascierto, P. A., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., Márquez-Rodas, I., Butler, M. O., Maio, M., Middleton, M. R., de la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A., Fecher, L. A., Millward, M., Khushalani, N. I., Queirolo, P., Lobo, M., de Pril, V., Loffredo, J., Larkin, J., & Weber, J. (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB & C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 21(11), 1465–1477. https://doi.org/10.1016/S1470-2045(20)30494-0

    Article  CAS  PubMed  Google Scholar 

  132. Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A. J. M., Grob, J. J., Gutzmer, R., Jamal, R., Lorigan, P., Ibrahim, N., Marreaud, S., van Akkooi, A. C. J., Suciu, S., & Robert, C. (2018). Adjuvant pembrolizumab versus placebo in resected stage III melanoma. The New England Journal of Medicine, 378(19), 1789–1801. https://doi.org/10.1056/NEJMoa1802357

    Article  CAS  PubMed  Google Scholar 

  133. Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Giacomo, A. M. D., Eertwegh, A. J. M., Grob, J.-J., Gutzmer, R., Jamal, R., Lorigan, P. C., Akkooi, A. C. J., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., & Robert, C. (2020). Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG/KEYNOTE-054 trial. Journal of Clinical Oncology, 38(33), 3925–3936. https://doi.org/10.1200/jco.20.02110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M. A., Millward, M., Patel, S. P., Haydon, A., Johnson, D. B., Lo, S., Blank, C. U., Sandhu, S., Carlino, M. S., Larkin, J. M. G., Menzies, A. M., & Long, G. V. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy(☆). Annals of Oncology, 31(8), 1075–1082. https://doi.org/10.1016/j.annonc.2020.04.471

    Article  CAS  PubMed  Google Scholar 

  135. Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Schadendorf, D., Lesimple, T., Plummer, R., Ji, R., Zhang, P., Mookerjee, B., Legos, J., Kefford, R., Dummer, R., & Kirkwood, J. M. (2017). Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. New England Journal of Medicine, 377(19), 1813–1823. https://doi.org/10.1056/NEJMoa1708539

    Article  CAS  Google Scholar 

  136. Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P. A., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Goodman, G. R., Simmons, B., Ye, C., Yan, Y., Schadendorf, D., Cinat, G., Fein, L. E., Brown, M., Guminski, A., Haydon, A., Khattak, A., McNeil, C., Parente, P., Power, J., Roberts-Thomson, R., Sandhu, S., Underhill, C., Varma, S., Berger, T., Awada, A., Blockx, N., Buyse, V., Mebis, J., Franke, F. A., Jobim de Azevedo, S., Silva Lazaretti, N., Jamal, R., Mihalcioiu, C., Petrella, T., Savage, K., Song, X., Wong, R., Dabelic, N., Plestina, S., Vojnovic, Z., Arenberger, P., Kocak, I., Krajsova, I., Kubala, E., Melichar, B., Vantuchova, Y., Putnik, K., Dreno, B., Dutriaux, C., Grob, J.-J., Joly, P., Lacour, J.-P., Meyer, N., Mortier, L., Thomas, L., Fluck, M., Gambichler, T., Hassel, J., Hauschild, A., Schadendorf, D., Donnellan, P., McCaffrey, J., Power, D., Ariad, S., Bar-Sela, G., Hendler, D., Ron, I., Schachter, J., Ascierto, P., Berruti, A., Bianchi, L., Chiarion Sileni, V., Cognetti, F., Danielli, R., Di Giacomo, A. M., Gianni, L., Goldhirsch, A., Guida, M., Maio, M., Mandalà, M., Marchetti, P., Queirolo, P., Santoro, A., Kapiteijn, E., Mackiewicz, A., Rutkowski, P., Ferreira, P., Demidov, L., Gafton, G., Makarova, Y., Andric, Z., Babovic, N., Jovanovic, D., Kandolf Sekulovic, L., Cohen, G., Dreosti, L., Vorobiof, D., Curiel Garcia, M. T., Diaz Beveridge, R., Majem Tarruella, M., Marquez Rodas, I., Puliats Rodriguez, J.-M., Rueda Dominguez, A., Maroti, M., Papworth, K., Michielin, O., Bondarenko, I., Brown, E., Corrie, P., Harries, M., Herbert, C., Kumar, S., Martin-Clavijo, A., Middleton, M., Patel, P., Talbot, T., Agarwala, S., Chapman, P., Conry, R., Doolittle, G., Gangadhar, T., Hallmeyer, S., Hamid, O., Hernandez-Aya, L., Johnson, D., Kass, F., Kolevska, T., Lewis, K., Lunin, S., Salama, A., Sikic, B., Somer, B., Spigel, D., & Whitman, E. (2018). Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Oncology, 19(4), 510–520. https://doi.org/10.1016/S1470-2045(18)30106-2

    Article  CAS  PubMed  Google Scholar 

  137. Hauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Haas, T., Shilkrut, M., Gasal, E., Kefford, R., Kirkwood, J. M., & Long, G. V. (2018). Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma. Journal of Clinical Oncology, 36(35), 3441–3449. https://doi.org/10.1200/jco.18.01219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Bhave, P., Pallan, L., Long, G. V., Menzies, A. M., Atkinson, V., Cohen, J. V., Sullivan, R. J., Chiarion-Sileni, V., Nyakas, M., Kahler, K., Hauschild, A., Plummer, R., Trojaniello, C., Ascierto, P. A., Zimmer, L., Schadendorf, D., Allayous, C., Lebbe, C., Maurichi, A., Santinami, M., Roy, S., Robert, C., Lesimple, T., Patel, S., Versluis, J. M., Blank, C. U., Khattak, A., Van der Westhuizen, A., Carlino, M. S., Shackleton, M., & Haydon, A. (2020). Melanoma recurrence patterns and management after adjuvant targeted therapy: A multicentre analysis. British Journal of Cancer. https://doi.org/10.1038/s41416-020-01121-y

  139. Khushalani, N. I., Kim, Y., Gibney, G. T., Kudchadkar, R. R., Eroglu, Z., Markowitz, J., Czupryn, M. P., Thebeau, M. S., McCormick, L., Richards, A., & Weber, J. S. (2016). Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL). Journal of Clinical Oncology, 34(15_suppl), 9586. https://doi.org/10.1200/JCO.2016.34.15_suppl.9586

    Article  Google Scholar 

  140. Squibb, B. M. Bristol Myers Squibb Announces Update on CheckMate −915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients. https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Announces-Update-on-CheckMate%2D%2D915-Evaluating-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Versus-Opdivo-in-Resected-High-Risk-Melanoma-Patients/default.aspx. Accessed 17 Jan 2021.

  141. Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015). Targeting the indoleamine 2,3-dioxygenase pathway in cancer. Journal for Immunotherapy of Cancer, 3, 51–51. https://doi.org/10.1186/s40425-015-0094-9

    Article  PubMed  PubMed Central  Google Scholar 

  142. Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005). Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine, 11(3), 312–319. https://doi.org/10.1038/nm1196

    Article  CAS  PubMed  Google Scholar 

  143. Yue, E. W., Sparks, R., Polam, P., Modi, D., Douty, B., Wayland, B., Glass, B., Takvorian, A., Glenn, J., Zhu, W., Bower, M., Liu, X., Leffet, L., Wang, Q., Bowman, K. J., Hansbury, M. J., Wei, M., Li, Y., Wynn, R., Burn, T. C., Koblish, H. K., Fridman, J. S., Emm, T., Scherle, P. A., Metcalf, B., & Combs, A. P. (2017). INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology. ACS Medicinal Chemistry Letters, 8(5), 486–491. https://doi.org/10.1021/acsmedchemlett.6b00391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Balmanoukian, A. S., Hamid, O., Gajewski, T. F., Frankel, A. E., Bauer, T. M., Olszanski, A. J., Luke, J. J., Schmidt, E. V., Sharkey, B., Maleski, J., Jones, M. J., & Gangadhar, T. C. (2017). 1214OEpacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037. Annals of Oncology, 28(suppl_5). https://doi.org/10.1093/annonc/mdx377.001

  145. Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., Demidov, L., Robert, C., Larkin, J., Anderson, J. R., Maleski, J., Jones, M., Diede, S. J., & Mitchell, T. C. (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): A phase 3, randomised, double-blind study. The Lancet Oncology, 20(8), 1083–1097. https://doi.org/10.1016/S1470-2045(19)30274-8

    Article  CAS  PubMed  Google Scholar 

  146. Daud, A., Saleh, M. N., Hu, J., Bleeker, J. S., Riese, M. J., Meier, R., Zhou, L., Serbest, G., & Lewis, K. D. (2018). Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study. Journal of Clinical Oncology, 36(15_suppl), 9511. https://doi.org/10.1200/JCO.2018.36.15_suppl.9511

    Article  Google Scholar 

  147. Labadie, B. W., Bao, R., & Luke, J. J. (2019). Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan–kynurenine–aryl hydrocarbon axis. Clinical Cancer Research, 25(5), 1462. https://doi.org/10.1158/1078-0432.CCR-18-2882

    Article  CAS  PubMed  Google Scholar 

  148. Naing, A., Eder, J. P., Piha-Paul, S. A., Gimmi, C., Hussey, E., Zhang, S., Hildebrand, V., Hosagrahara, V., Habermehl, C., Moisan, J., & Papadopoulos, K. P. (2020). Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-000870

  149. Goldberg, M. V., & Drake, C. G. (2011). LAG-3 in cancer immunotherapy. Current Topics in Microbiology and Immunology, 344, 269–278. https://doi.org/10.1007/82_2010_114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Ascierto, P. A., Melero, I., Bhatia, S., Bono, P., Sanborn, R. E., Lipson, E. J., Callahan, M. K., Gajewski, T., Gomez-Roca, C. A., Hodi, F. S., Curigliano, G., Nyakas, M., Preusser, M., Koguchi, Y., Maurer, M., Clynes, R., Mitra, P., Suryawanshi, S., & Muñoz-Couselo, E. (2017). Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. Journal of Clinical Oncology, 35(15_suppl), 9520. https://doi.org/10.1200/JCO.2017.35.15_suppl.9520

    Article  Google Scholar 

  151. Ascierto, P. A., Bono, P., Bhatia, S., Melero, I., Nyakas, M. S., Svane, I., Larkin, J., Gomez-Roca, C., Schadendorf, D., Dummer, R., Marabelle, A., Hoeller, C., Maurer, M., Harbison, C. T., Mitra, P., Suryawanshi, S., Thudium, K., & Couselo, E. M. (2017). Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in Pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Annals of Oncology, 28(suppl_5), v605–v649. https://doi.org/10.1093/annonc/mdx440

    Article  Google Scholar 

  152. Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S., Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T., & Wargo, J. A. (2018). Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 24(11), 1649–1654. https://doi.org/10.1038/s41591-018-0197-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017). The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy, 9(8), 681–692. https://doi.org/10.2217/imt-2017-0024

    Article  CAS  PubMed  Google Scholar 

  154. Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. The Journal of Experimental Medicine, 207(10), 2175–2186. https://doi.org/10.1084/jem.20100637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of Experimental Medicine, 207(10), 2187–2194. https://doi.org/10.1084/jem.20100643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020). T-cell agonists in cancer immunotherapy. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-000966

  157. Peng, W., Williams, L. J., Xu, C., Melendez, B., McKenzie, J. A., Chen, Y., Jackson, H. L., Voo, K. S., Mbofung, R. M., Leahey, S. E., Wang, J., Lizee, G., Tawbi, H. A., Davies, M. A., Hoos, A., Smothers, J., Srinivasan, R., Paul, E. M., Yanamandra, N., & Hwu, P. (2019). Anti-OX40 antibody directly enhances the function of tumor-reactive CD8<sup>+</sup> T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. Clinical Cancer Research, 25(21), 6406–6416. https://doi.org/10.1158/1078-0432.Ccr-19-1259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Buchan, S. L., Rogel, A., & Al-Shamkhani, A. (2018). The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood, 131(1), 39–48. https://doi.org/10.1182/blood-2017-07-741025

    Article  CAS  PubMed  Google Scholar 

  159. Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., Moudgil, T., Miller, W., Haley, D., Coffey, T., Fisher, B., Delanty-Miller, L., Rymarchyk, N., Kelly, T., Crocenzi, T., Bernstein, E., Sanborn, R., Urba, W. J., & Weinberg, A. D. (2013). OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Research, 73(24), 7189–7198. https://doi.org/10.1158/0008-5472.Can-12-4174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Glisson, B. S., Leidner, R. S., Ferris, R. L., Powderly, J., Rizvi, N. A., Keam, B., Schneider, R., Goel, S., Ohr, J. P., Burton, J., Zheng, Y., Eck, S., Gribbin, M., Streicher, K., Townsley, D. M., & Patel, S. P. (2020). Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors. Clinical Cancer Research, 26(20), 5358–5367. https://doi.org/10.1158/1078-0432.Ccr-19-3070

    Article  CAS  PubMed  Google Scholar 

  161. Oberst, M. D., Auge, C., Morris, C., Kentner, S., Mulgrew, K., McGlinchey, K., Hair, J., Hanabuchi, S., Du, Q., Damschroder, M., Feng, H., Eck, S., Buss, N., de Haan, L., Pierce, A. J., Park, H., Sylwester, A., Axthelm, M. K., Picker, L., Morris, N. P., Weinberg, A., & Hammond, S. A. (2018). Potent immune modulation by MEDI6383, an engineered human OX40 ligand IgG4P fc fusion protein. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-17-0200

  162. Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018). Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical results, and future strategies. Blood, 131(1), 49–57. https://doi.org/10.1182/blood-2017-06-741041

    Article  CAS  PubMed  Google Scholar 

  163. Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., & Logan, T. (2008). Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). Journal of Clinical Oncology, 26(15_suppl), 3007. https://doi.org/10.1200/jco.2008.26.15_suppl.3007

    Article  Google Scholar 

  164. Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M., & Levy, R. (2017). Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clinical Cancer Research, 23(8), 1929–1936. https://doi.org/10.1158/1078-0432.Ccr-16-1272

    Article  CAS  PubMed  Google Scholar 

  165. Massarelli, E., Segal, N., Ribrag, V., Melero, I., Gangadhar, T., & Urba, W. (2016). Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies. Journal for Immunotherapy of Cancer, 4(Suppl 1), O7.

    Google Scholar 

  166. Tolcher, A. W., Sznol, M., Hu-Lieskovan, S., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Di Gravio, D., Huang, B., Gambhire, D., Chen, Y., Thall, A. D., Pathan, N., Schmidt, E. V., & Chow, L. Q. M. (2017). Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clinical Cancer Research, 23(18), 5349–5357. https://doi.org/10.1158/1078-0432.Ccr-17-1243

    Article  CAS  PubMed  Google Scholar 

  167. Brunn, N. D., Mauze, S., Gu, D., Wiswell, D., Ueda, R., Hodges, D., Beebe, A. M., Zhang, S., & Escandón, E. (2016). The role of anti-drug antibodies in the pharmacokinetics, disposition, target engagement, and efficacy of a GITR agonist monoclonal antibody in mice. Journal of Pharmacology and Experimental Therapeutics, 356(3), 574–586. https://doi.org/10.1124/jpet.115.229864

    Article  CAS  Google Scholar 

  168. Papadopoulos, K. P., Autio, K. A., Golan, T., Dobrenkov, K., Chartash, E., Li, X. N., Wnek, R., & Long, G. V. (2019). Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology, 37(15_suppl), 9509–9509. https://doi.org/10.1200/JCO.2019.37.15_suppl.9509

    Article  Google Scholar 

  169. Geva, R., Voskoboynik, M., Dobrenkov, K., Mayawala, K., Gwo, J., Wnek, R., Chartash, E., & Long, G. V. (2020). First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer, 126(22), 4926–4935. https://doi.org/10.1002/cncr.33133

    Article  CAS  PubMed  Google Scholar 

  170. Lopes, J. E., Fisher, J. L., Flick, H. L., Wang, C., Sun, L., Ernstoff, M. S., Alvarez, J. C., & Losey, H. C. (2020). ALKS 4230: A novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Journal for Immunotherapy of Cancer, 8(1), e000673. https://doi.org/10.1136/jitc-2020-000673

    Article  PubMed  PubMed Central  Google Scholar 

  171. Charych, D. H., Hoch, U., Langowski, J. L., Lee, S. R., Addepalli, M. K., Kirk, P. B., Sheng, D., Liu, X., Sims, P. W., VanderVeen, L. A., Ali, C. F., Chang, T. K., Konakova, M., Pena, R. L., Kanhere, R. S., Kirksey, Y. M., Ji, C., Wang, Y., Huang, J., Sweeney, T. D., Kantak, S. S., & Doberstein, S. K. (2016). NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clinical Cancer Research, 22(3), 680. https://doi.org/10.1158/1078-0432.CCR-15-1631

    Article  CAS  PubMed  Google Scholar 

  172. Bentebibel, S.-E., Hurwitz, M. E., Bernatchez, C., Haymaker, C., Hudgens, C. W., Kluger, H. M., Tetzlaff, M. T., Tagliaferri, M. A., Zalevsky, J., Hoch, U., Fanton, C., Aung, S., Hwu, P., Curti, B. D., Tannir, N. M., Sznol, M., & Diab, A. (2019). A first-in-human study and biomarker analysis of NKTR-214, a novel IL-2-receptor beta/gamma (βγ)-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discovery, CD-18-1495. https://doi.org/10.1158/2159-8290.Cd-18-1495.

  173. Diab, A., Tykodi, S., Daniels, G., Maio, M., Curti, B., Lewis, K., Jang, S., Kalinka, E., Puzanov, I., Spira, A., Cho, D., Guan, S., Puente, E., Hoch, U., Currie, S., Nguyen, T., Lin, W., Tagliaferri, M., Zalevsky, J., Sznol, M., & Hurwitz, M. (2020). 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: Results from the PIVOT-02 study. Journal for Immunotherapy of Cancer, 8(Suppl 3), A256–A256. https://doi.org/10.1136/jitc-2020-SITC2020.0420

    Article  Google Scholar 

  174. Vaishampayan, U. N., Muzaffar, J., Velcheti, V., Winer, I., Hoimes, C. J., Rosen, S. D., Spreafico, A., McDermott, D. F., Chu, Q. S. C., Dumas, O., Gilbert, L., Hirte, H., Curtis, K. K., Du, Y., Bidollari, I., Sun, L., Putiri, E., Losey, H. C., Dezube, B., & Ernstoff, M. S. (2020). 1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1). Annals of Oncology, 31, S708–S709. https://doi.org/10.1016/j.annonc.2020.08.1147

    Article  Google Scholar 

  175. Fromm, G., de Silva, S., Johannes, K., Patel, A., Hornblower, J. C., & Schreiber, T. H. (2018). Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. Journal for Immunotherapy of Cancer, 6(1), 149. https://doi.org/10.1186/s40425-018-0454-3

    Article  PubMed  PubMed Central  Google Scholar 

  176. Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., Cogdill, A. P., Zhao, L., Hudgens, C. W., Hutchinson, D. S., Manzo, T., Petaccia de Macedo, M., Cotechini, T., Kumar, T., Chen, W. S., Reddy, S. M., Szczepaniak Sloane, R., Galloway-Pena, J., Jiang, H., Chen, P. L., Shpall, E. J., Rezvani, K., Alousi, A. M., Chemaly, R. F., Shelburne, S., Vence, L. M., Okhuysen, P. C., Jensen, V. B., Swennes, A. G., McAllister, F., Marcelo Riquelme Sanchez, E., Zhang, Y., Le Chatelier, E., Zitvogel, L., Pons, N., Austin-Breneman, J. L., Haydu, L. E., Burton, E. M., Gardner, J. M., Sirmans, E., Hu, J., Lazar, A. J., Tsujikawa, T., Diab, A., Tawbi, H., Glitza, I. C., Hwu, W. J., Patel, S. P., Woodman, S. E., Amaria, R. N., Davies, M. A., Gershenwald, J. E., Hwu, P., Lee, J. E., Zhang, J., Coussens, L. M., Cooper, Z. A., Futreal, P. A., Daniel, C. R., Ajami, N. J., Petrosino, J. F., Tetzlaff, M. T., Sharma, P., Allison, J. P., Jenq, R. R., & Wargo, J. A. (2018). Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 359(6371), 97. https://doi.org/10.1126/science.aan4236

    Article  CAS  PubMed  Google Scholar 

  177. Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B. (2020). Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. https://doi.org/10.1126/science.abb5920

Download references

Author information

Authors and Affiliations

  1. Department of Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Houston, TX, USA

    Justin T. Moyers

  2. Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, Orange, CA, USA

    Justin T. Moyers

  3. Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA

    Isabella C. Glitza Oliva

Authors
  1. Justin T. Moyers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabella C. Glitza Oliva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isabella C. Glitza Oliva .

Editor information

Editors and Affiliations

  1. Professor, Dept. of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Aung Naing

  2. Assistant Professor, Service Chief of Adult Allergy & Immunology, Division of Immunology, Allergy & Retrovirology Baylor College of Medicine and Texas Children’ Hospital, Houston, TX, USA

    Joud Hajjar

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Moyers, J.T., Glitza Oliva, I.C. (2021). Immunotherapy for Melanoma. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 1342. Springer, Cham. https://doi.org/10.1007/978-3-030-79308-1_3

Download citation

Publish with us

Policies and ethics

Search

Navigation